Pharmgroup

PharmGroup is presented as a holding company operating in the pharmaceutical market with a focus on both wholesale and retail of medicines and medical devices. According to the available information, the group was established on May 15, 2008, and over time has developed a network of subsidiaries designed to support various aspects of pharmaceutical distribution and marketing. The company describes itself as benefiting from a combination of strong personnel and a robust policy framework, together with an in-house computer program intended to support analysis and operational calculations.

The structure of PharmGroup is described as a holding that includes several subsidiary entities, each performing a distinct activity within the broader pharmaceutical sphere:

- Pharm Service and Norma Plus are noted as marketing-oriented divisions responsible for the promotion and marketing of new products that may be less known in the market.

- Zeferan is described as an owned chain of pharmacies, expanding the retail footprint of the group.

- GMC is cited as the entity handling tender activities within the holding, suggesting participation in procurement and competitive bidding processes.

- PharmGroup itself is positioned as the wholesale arm of the organization, coordinating the distribution of products to various clients.

The group reportedly employs a sizable workforce, with an overall staff count around 500 employees. Of these, approximately 200 work directly under PharmGroup, with additional staff distributed across marketing (about 120), Zeferan pharmacies (around 150), and GMC (approximately 20). The scale of operations is further supported by large stock facilities, including warehouses totaling around 5,000 square meters. These facilities are described as meeting European standards and include the logistics capabilities required for delivering medicines to clients both within the main city (Baku) and across other regions.

A core strategic objective highlighted by PharmGroup is to improve population access to high-quality medicinal products. The company emphasizes the development of a pharmacy chain that adheres to European standards, including appropriate storage practices for over-the-counter products, compliance with product handling requirements, and selection of properly certified items for sale. At the time of the profile, the Zeferan brand was already associated with 27 functioning pharmacies, with a plan to expand further and house approximately 45 additional pharmacies under construction.

Overall, PharmGroup presents itself as a diversified pharmaceutical group with wholesale distribution capabilities, a targeted marketing and promotion function, and an expanding network of retail pharmacies. The combination of sizeable warehousing, a structured multi-entity setup, and a focus on quality and accessibility underscores the organization’s approach to sustaining and growing its presence in the pharmaceutical sector.